MDACC Study No:2013-0225 ( NCT No: NCT01893372)
Title:Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients with MDS
Principal Investigator:Courtney DiNardo
Treatment Agent:Azacitidine; Decitabine; Eltrombopag
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if eltrombopag can help to
control MDS. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Azacitidine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:GlaxoSmithKline
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Courtney DiNardo
For Clinical Trial Enrollment:713-794-1141
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults